Maller R, Isaksson B, Nilsson L, Sörén L
Department of Infectious Diseases, University Hospital, Linköping, Sweden.
J Antimicrob Chemother. 1988 Jul;22(1):75-9. doi: 10.1093/jac/22.1.75.
Forty-five mostly elderly patients with serious infections were treated in a prospective, comparative and randomized pharmacokinetic study with amikacin 11.0 or 15.0 mg/kg administered in a single daily dose as an intravenous, short-term infusion or with amikacin 7.5 mg/kg administered twice daily in the same way. The results indicate that administration of amikacin 15 mg/kg in a single daily dose should be a practical and safe principle of administration. However elderly patients often have reduced creatinine clearance and should preferably be given a lower dose of 11 mg/kg bw. The risk of nephrotoxicity did not increase, but conclusions on ototoxicity and clinical efficacy cannot be drawn from this limited study. This should be considered as an initial part of a future multicentre trial.
45名主要为老年的严重感染患者参与了一项前瞻性、比较性和随机化的药代动力学研究，分别接受每日单次静脉短期输注11.0或15.0mg/kg的阿米卡星治疗，或以同样方式每日两次接受7.5mg/kg的阿米卡星治疗。结果表明，每日单次给予15mg/kg的阿米卡星应是一种实用且安全的给药原则。然而，老年患者的肌酐清除率通常会降低，最好给予较低剂量的11mg/kg体重。肾毒性风险并未增加，但由于这项有限的研究，无法得出关于耳毒性和临床疗效的结论。这应被视为未来多中心试验的初始部分。
